The Rheumatologist
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
  • Technology
    • Electronic Health Records
    • Apps
    • Information Technology
  • Resources
    • Issue Archives
    • Events
    • Multimedia
      • Audio
      • Video
    • From the College
    • American College of Rheumatology
    • Rheumatology Research Foundation
    • Arthritis & Rheumatology
    • Arthritis Care & Research
    • Treatment Guidelines
    • Research Reviews
    • Annual Meeting
      • Abstracts
      • Meeting Reports
    • Rheumatology Image Bank
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / RA & Huntington’s Disease: New Epigenetic Technology Uncovers Overlap

RA & Huntington’s Disease: New Epigenetic Technology Uncovers Overlap

November 18, 2018 • By Catherine Kolonko

  • Tweet
  • Email
Print-Friendly Version / Save PDF
petarg / shutterstock.com

petarg / shutterstock.com

Researchers working to decode the epigenetic landscape for rheuma­toid arthritis (RA) were surprised to discover a connection to Huntington’s disease, a finding that could pave the way to discoveries of new therapeutic targets.

You Might Also Like
  • Switches That Regulate Gene Expression Offer Better Understanding of Rheumatic Disease Say Experts at the 2013 ACR/ARHP Annual Meeting
  • DNA Methylation Modifies Genetic Risk for Rheumatoid Arthritis
  • Study Uncovers Tet2’s Role in Resolving Inflammation
Explore this issue
November 2018
Also by this Author
  • FOCIS 2015: TET Protein Regulation May Provide Insights for Cancer Treatment

By developing new methods to integrate data from epigenetic technologies, scientists at the University of California, San Diego (UCSD), set out to map the epigenome of rheumatoid arthritis and discovered potential, non-obvious biological targets for treatment of the disease. The findings were published in the May issue of Nature Communications.1

“We were most interested in identifying disease mechanisms that were not predictable, creating the opportunity to understand disease in a way that could not have been gleaned from simply looking at published reports,” says Gary S. Firestein, MD, dean and associate vice chancellor of translational medicine at UCSD.

Epigenetics is the study of DNA modifications that alter the genome without a change to DNA sequence; this process is responsible for some of the fine-tuning of gene expression, explains Dr. Firestein. Changes in the epigenome can help determine which genes are turned on or off and can be triggered by a variety of environmental elements, such as stress, physical activity and lifestyle choices.

Although epigenetic function is part of normal human growth and development, it can also go badly wrong and, ultimately, cause diseases, such as cancer, or contribute to the pathogenesis of diseases, such as in rheumatoid arthritis, says Dr. Firestein. “The changes that occur with rheumatologic diseases are much more subtle than cancer,” he says. “Generally, we are talking about relatively modest changes that just tweak cell behavior.”

Mapping the Epigenomic Landscape of RA

Dr. Firestein

Dr. Firestein

Dr. Firestein and his team of researchers investigated the fibroblast-like cells that line the joints of patients with rheumatoid arthritis as well as those of osteoarthritis patients who served as a control group. To begin the process of mapping the epigenomic landscape of RA, they analyzed 191 data sets through examination and measurement of chromatin, DNA and histone modifications from both RA and osteoarthritis patients.

To maximize the potential for identifying differences in RA, researchers used cells from patients with late-stage disease. They focused on isolated cells collected at the time of surgery from the tissue of people who had total joint replacement.

“We fully profiled key epigenetic marks in RA patients and compared them to individuals who did not have this disease,” says Dr. Firestein. “As a control, for example, we used osteoarthritis because that is not generally considered an autoimmune disease.”

Pages: 1 2 3 Single Page

Filed Under: Conditions, Research Reviews, Rheumatoid Arthritis Tagged With: epigenetics, epigenomeIssue: November 2018

You Might Also Like:
  • Switches That Regulate Gene Expression Offer Better Understanding of Rheumatic Disease Say Experts at the 2013 ACR/ARHP Annual Meeting
  • DNA Methylation Modifies Genetic Risk for Rheumatoid Arthritis
  • Study Uncovers Tet2’s Role in Resolving Inflammation
  • Opinion: Erosive Changes Questioned in RA/Lupus Overlap Syndrome

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR/ARP Annual Meeting

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Annual Meeting site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2019 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.